Device Trial Radar · NCT07430293
Hybrid Closed-Loop Insulin Delivery After Pancreatectomy
Last checked: Nov 20, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
May 19, 2026
Primary completion
Nov 19, 2027
Study completion Nov 19, 2027
Sponsor
- Lead sponsor
- Centre Hospitalier Sud FrancilienAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 24, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Individuals with diabetes secondary to pancreatectomy experience impaired quality of life, partly due to the challenges of managing highly variable blood glucose levels. Hybrid closed-loop (HCL) automated insulin delivery (AID) systems, widely evaluated in type 1 diabetes, may improve both metabolic outcomes and quality of life in this population. A review of the literature identified a few observational studies reporting promising results with HCL systems in the context of post-pancreatectomy diabetes. Only one randomized trial has evaluated AID in this population, showing excellent outcomes, but using a complex bihormonal system that is not yet commercially available worldwide. Consequently, there remains a lack of confirmatory evidence regarding the efficacy of commercially available monohormonal HCL systems in individuals with diabetes secondary to pancreatectomy, evidence that is crucial to support broader access to this technology. The intervention will consist in a 3-month AID treatment combining MiniMed 780 and Simplera. The control period will consist in 3 months using the Simplera for continuous glucose monitoring, alongside participant usual diabetes treatment. The primary outcome is the percentage of time that interstitial glucose levels remain within the target range (70-180 mg/dL), as measured by continuous glucose monitoring (CGM, Simplera), over a 3-month period using the MiniMed 780 hybrid closed-loop system, compared to a 3-month period under the participant's usual diabetes treatment.
Conditions
- Pancreatectomy
- Total Pancreatectomy
- Partial Pancreatectomy
Interventions
MiniMed 780 associated with SimpleraDevice
MiniMed 780 associated with Simplera
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of time in rangeTime frame: At 3 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Centre Hospitalier Sud Francilien
Corbeil-Essonnes, France, France · Recruiting
Hôpital Bichat (APHP)
Paris, France, France · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.